| Burn-out an “occupational phenomenon”: International Classification of Diseases World Health Organization | 2989* | 2019 |
| Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients Y Miyazaki, L Glass, C Triplitt, M Matsuda, K Cusi, A Mahankali, ... Diabetologia 44, 2210-2219, 2001 | 379 | 2001 |
| Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus Y Miyazaki, L Glass, C Triplitt, E Wajcberg, LJ Mandarino, RA DeFronzo American Journal of Physiology-Endocrinology and Metabolism 283 (6), E1135-E1143, 2002 | 339 | 2002 |
| Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E … MA Abdul‐Ghani, C Puckett, C Triplitt, D Maggs, J Adams, E Cersosimo, ... Diabetes, Obesity and Metabolism 17 (3), 268-275, 2015 | 220 | 2015 |
| Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes A Cervera, E Wajcberg, A Sriwijitkamol, M Fernandez, P Zuo, C Triplitt, ... American Journal of Physiology-Endocrinology and Metabolism 294 (5), E846-E852, 2008 | 205 | 2008 |
| Pathogenesis of type 2 diabetes mellitus E Cersosimo, C Triplitt, C Solis-Herrera, LJ Mandarino, RA DeFronzo Endotext, 12-16, 2000 | 160 | 2000 |
| Rosiglitazone decreases albuminuria in type 2 diabetic patients Y Miyazaki, E Cersosimo, C Triplitt, RA DeFronzo Kidney international 72 (11), 1367-1373, 2007 | 151 | 2007 |
| Drug interactions of medications commonly used in diabetes C Triplitt Diabetes Spectrum 19 (4), 202, 2006 | 143 | 2006 |
| Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate JE Galgani, LK Heilbronn, K Azuma, DE Kelley, JB Albu, X Pi-Sunyer, ... Diabetes 57 (4), 841-845, 2008 | 141 | 2008 |
| Understanding the kidneys' role in blood glucose regulation CL Triplitt American Journal of Managed Care 18 (1), S11, 2012 | 136 | 2012 |
| Effects of exenatide plus rosiglitazone on β-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin RA DeFronzo, C Triplitt, Y Qu, MS Lewis, D Maggs, LC Glass Diabetes care 33 (5), 951-957, 2010 | 132 | 2010 |
| Examining the mechanisms of glucose regulation CL Triplitt American Journal of Managed Care 18 (1), S4, 2012 | 119 | 2012 |
| Novel agents for the treatment of type 2 diabetes RA DeFronzo, CL Triplitt, M Abdul-Ghani, E Cersosimo Diabetes Spectrum 27 (2), 100-112, 2014 | 102 | 2014 |
| Classification of diabetes mellitus C Solis-Herrera, C Triplitt, C Reasner, RA DeFronzo, E Cersosimo | 99 | 2015 |
| Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study A Gastaldelli, M Gaggini, G Daniele, D Ciociaro, E Cersosimo, D Tripathy, ... Hepatology 64 (6), 2028-2037, 2016 | 96 | 2016 |
| Physiological and molecular determinants of insulin action in the baboon AO Chavez, JC Lopez-Alvarenga, ME Tejero, C Triplitt, RA Bastarrachea, ... Diabetes 57 (4), 899-908, 2008 | 93 | 2008 |
| Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus H Al Jobori, G Daniele, J Adams, E Cersosimo, C Solis-Herrera, C Triplitt, ... The Journal of Clinical Endocrinology & Metabolism 103 (4), 1402-1407, 2018 | 82 | 2018 |
| Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients H Al Jobori, G Daniele, J Adams, E Cersosimo, C Triplitt, RA DeFronzo, ... Diabetes, Obesity and Metabolism 19 (6), 809-813, 2017 | 79 | 2017 |
| Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study C Solis-Herrera, C Triplitt, JJ Garduno-Garcia, J Adams, RA DeFronzo, ... Diabetes care 36 (9), 2756-2762, 2013 | 79 | 2013 |
| New technologies and therapies in the management of diabetes CL Triplitt Am J Manag Care 13 (Suppl 2), S47-54, 2007 | 79 | 2007 |
